<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398450</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-060199</org_study_id>
    <secondary_id>CDR0000511743</secondary_id>
    <secondary_id>PHARMION-UCSD-060199</secondary_id>
    <nct_id>NCT00398450</nct_id>
  </id_info>
  <brief_title>Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Phase I Study of 5-azacytidine (Vidaza) With Interferon α2b in Metastatic Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Interferon alfa may interfere with the growth of tumor cells. Giving azacitidine together&#xD;
      with interferon alfa may be an effective treatment for melanoma.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of azacitidine when&#xD;
      given together with interferon alfa in treating patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of azacitidine in combination with interferon&#xD;
           alfa-2b in patients with metastatic melanoma.&#xD;
&#xD;
        -  Determine if the MTD of this regimen is biologically active in these patients.&#xD;
&#xD;
        -  Define and describe the toxicities associated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the response in patients treated with this regimen.&#xD;
&#xD;
        -  Describe, preliminarily, the time to progression and overall survival of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of azacitidine.&#xD;
&#xD;
      Patients receive azacitidine subcutaneously (SC) once daily on days 1-5 (week 1) followed by&#xD;
      interferon alfa-2b SC 3 days a week in weeks 2-4. Treatment repeats every 28 days for up to 6&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of azacitidine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at day 1, 12 months, 3 years, and 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa-2b</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma&#xD;
&#xD;
          -  At least one lesion appropriate for 3 separate punch or core needle biopsies&#xD;
&#xD;
          -  Must have received and failed ≥ 1 prior systemic treatment for metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known allergies to azacitidine, interferon alfa, benzyl alcohol, or mannitol&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No hepatitis B or hepatitis C infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior systemic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy to target lesions with evidence of&#xD;
             progression&#xD;
&#xD;
          -  No concurrent radiotherapy to target lesions&#xD;
&#xD;
          -  No concurrent oral or IV corticosteroids&#xD;
&#xD;
               -  Topical creams or ocular steroid drops are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A. Daniels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Gregory Daniels</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

